The Emerging Role of Local Therapy in Metastatic Prostate Cancer.
Hormone therapy–relapsed prostate cancer
Hormone-sensitive prostate cancer
Prostate cancer
Radiotherapy
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
20 01 2020
20 01 2020
Historique:
entrez:
22
1
2020
pubmed:
22
1
2020
medline:
22
6
2021
Statut:
epublish
Résumé
This review summarizes the prospective clinical evidence regarding local therapy in metastatic prostate cancer. The phase 3 STAMPEDE trial showed that prostate radiotherapy confers a survival benefit for newly diagnosed patients with low volume metastatic hormone-sensitive prostate cancer (HSPC). No survival benefit was noted for those with high volume disease. A subsequent meta-analysis combining the data of the STAMPEDE trial with that of the HORRAD trial corroborated these findings. The phase 2 randomized STOMP trial investigated local treatment of metastases in patients with oligometastatic HSPC, and showed an improvement in hormone therapy-free survival. Local prostate radiotherapy should be offered to patients with newly diagnosed low volume metastatic HSPC. Early clinical evidence suggests that local treatment to metastatic disease might be beneficial for patients with oligometastatic HSPC, but larger trials are awaited.
Identifiants
pubmed: 31960153
doi: 10.1007/s11912-020-0868-1
pii: 10.1007/s11912-020-0868-1
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Références
Lancet Oncol. 2009 Jul;10(7):718-26
pubmed: 19573801
Eur Urol. 2015 May;67(5):852-63
pubmed: 25240974
Cancer Discov. 2018 Apr;8(4):444-457
pubmed: 29367197
Cancer Cell. 2009 Jan 6;15(1):35-44
pubmed: 19111879
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Int J Cancer. 2018 Sep 1;143(5):1236-1248
pubmed: 29574703
Eur Urol. 2019 Jul;76(1):115-124
pubmed: 30826218
J Clin Oncol. 2016 Aug 20;34(24):2835-42
pubmed: 27325855
Eur Urol. 2019 Mar;75(3):410-418
pubmed: 30266309
BMJ. 2010 Mar 30;340:c117
pubmed: 20354011
Cell. 2013 Nov 7;155(4):750-64
pubmed: 24209616
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Eur Urol. 2014 Jun;65(6):1058-66
pubmed: 24290503
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
Mol Cancer. 2017 Dec 02;16(1):176
pubmed: 29197379
Eur Urol. 2015 Jan;67(1):3-6
pubmed: 25217422
Nature. 2005 Dec 8;438(7069):820-7
pubmed: 16341007
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Nat Rev Clin Oncol. 2011 Jun 07;8(8):504-6
pubmed: 21647193
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
BMC Cancer. 2014 Sep 15;14:671
pubmed: 25223986
Lancet Oncol. 2016 Dec;17(12):1672-1682
pubmed: 27789196
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Clin Oncol (R Coll Radiol). 2019 Dec;31(12):824-833
pubmed: 31182289
CA Cancer J Clin. 2017 Jan;67(1):65-85
pubmed: 27570942
Eur Urol. 2019 May;75(5):707-711
pubmed: 30665814
Nat Cell Biol. 2006 Dec;8(12):1369-75
pubmed: 17128264
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Nat Commun. 2018 Mar 21;9(1):1176
pubmed: 29563510
Sci Transl Med. 2015 Nov 4;7(312):312re10
pubmed: 26537258
Eur Urol. 2014 Sep;66(3):602-3
pubmed: 24821581
Eur Urol. 2019 Apr;75(4):667-675
pubmed: 30638634
Nat Rev Cancer. 2009 Apr;9(4):285-93
pubmed: 19308068
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
Cell. 2008 Apr 4;133(1):66-77
pubmed: 18394990